Aurobindo Pharma shares rise 2% on USFDA approval for asthma drug
Aurobindo Pharma has received approval from USFDA to produce and trade Budesonide Inhalation Suspension
asthma drug
November 2023
January 2023
Lupin launches asthma drug DIFIZMA; stock gains
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
